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Abstract
Purpose:  To  retrospectively  compare  three-dimensional  ultrasonography  (3D-US)  and  pelvic  X-
rays to  assess  the  position  of  tubal  sterilization  microinserts.
Material  and  methods:  Forty-four  patients  who  underwent  tubal  sterilization  with  Essure®
microinserts  in  our  institution  were  included.  The  microinserts’position  was  evaluated  three
months  after  the  procedure  using  3D-US  and  pelvic  X-rays.  Placement  on  3D-US  was  binary
categorized  as  correct  or  incorrect  and  the  distance  between  the  two  devices  was  reported.
The orientation  and  symmetric  deployment  of  the  microinserts  and  the  distance  between  the
proximal parts  of  the  two  devices  was  assessed  on  pelvic  X-rays.  Performance  of  3D-US  and
pelvic X-ray  were  compared  using  Mac  Nemar  test.  Comparison  of  the  distance  between  the
two devices  measured  on  pelvic  X-rays  and  3D-US  was  made  with  the  paired  Student  t  test.
Results: 3D-US  images  showed  microinserts  in  93%  (41/44).  Eighty-six  percent  (38/44)  were  cor-
rectly positioned  on  3D-US  and  82%  (36/44)  on  pelvic  X-rays.  No  signiﬁcant  differences  between
the performances  of  the  two  imaging  techniques  were  found.  No  signiﬁcant  differences  for  the
distance between  the  two  devices  measured  on  pelvic  X-ray  and  3D-US  was  found.
Conclusion:  3D-US  is  a  simple,  non-ionizing  technique,  which  appears  as  a  promising  alternate
technique  to  pelvic  X-rays  to  assess  the  correct  position  of  Essure® microinserts.© 2015  Éditions  franc¸aises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
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Tubal  sterilization  is  the  most  commonly  used  contracep-
ive  method  in  the  world  [1].  Hysteroscopic  sterilization  is  a
ell-tolerated  procedure  [1,2]  avoiding  general  anaesthesia
3,4]  and  surgical  incision  [5]  and  the  Essure® microinserts
Conceptus,  Inc.,  San  Carlos,  CA,  USA)  were  ﬁrst  approved  in
he  USA  in  2002  [6,7].  It  is  a  permanent  birth  control  device
ith  an  efﬁciency  rate  at  5-years  around  99%  [8—11].
Optimal  positioning  of  the  microinsert  is  needed  to
btain  ﬁbrotic  reaction  and  subsequent  tubal  occlusion.
onsequently,  correct  position  is  usually  ascertained  three
onths  after  placement  [6,12,13].  The  imaging  techniques
sed  for  ascertaining  the  correct  position  may  vary  among
ountries  [13—17].  Hysterosalpingography  (remains  the  gold
tandard  and  is  currently  recommended  by  the  Food  and
rug  Administration  (FDA)  [18—21]  whereas  pelvic  X-rays  are
ecommended  in  Europe  [12].  The  new  recommendations
rom  the  manufacturer  advise  to  perform  a  pelvic  X-ray  in
rst  intention  three  months  after  the  procedure.  Hysteros-
lpingography  needs  to  be  performed  when  the  procedure
s  complicated  or  if  pelvic  X-rays  do  not  conﬁrm  correct
ositioning  of  the  devices.
According  to  Thiels  et  al.  [17],  two-dimensional  (2D-US)
nd  three-dimensional  ultrasonography  (3D-US)  are  excel-
ent  alternatives  to  pelvic  X-rays  or  hysterosalpingography
o  conﬁrm  the  correct  position  of  the  Essure  coils  3  months
fter  the  procedure  [17].
The  purpose  of  our  retrospective  study  was  to  compare
he  performance  of  pelvic  X-rays  with  those  of  3D-US  to
ssess  the  position  of  Essure  microinserts  three  months  after
ysteroscopic  sterilization.
aterials and methods
tudy population
his  retrospective  study  was,  approved  by  our  institutional
eview  board.  Fifty-two  women  underwent  hysteroscopic
terilization  in  our  institution  (University  Hospital)  between
ay  2010  and  September  2012  inclusively.  Patients  were
xcluded  if  they  underwent  hysterosalpingography  ﬁrst
ecause  of  complications  or  suspected  failure  during  hys-
eroscopic  procedure  (1  patient),  if  they  had  history  of
nilateral  salpingectomy  (2  patients)  or  if  3D-US  was  not
vailable  for  review  (5  patients).  Finally,  44  women  who
nderwent  3D-US  and  pelvic  X-rays  were  included  in  our
tudy.
ubal sterilization procedure
he  sterilization  procedure  was  carried  out  in  an  operating
oom  without  general  anesthesia  and  in  an  ambulatory  set-
ing. The  procedure  was  performed  during  the  7th—14th  day
f  the  menstrual  cycle  and  a  pregnancy  test  was  conducted
ithin  24  hours  before  the  procedure  [22].
A  rigid  hysteroscope,  with  a  camera,  was  introduced  into
he  uterine  cavity  and  a  saline  solution  was  instillated  to  dis-
end  the  uterus.  Both  tubal  ostia  were  identiﬁed,  and  the
icroinserts  were  placed  into  the  proximal  portion  of  the
allopian  tube  using  hysteroscopic  guidance  [12]; the  devices
ere  then  deployed  [22].  The  gynaecologists  considered
a
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hat  the  Essure  were  correctly  positioned  when  3—8  coils
ere  visible  into  the  uterine  cavity  during  hysteroscopy.
maging procedure
elvic  X-rays  and  3D-US  were  performed  three  months  after
ysteroscopic  sterilization.
Plain  anterior-posterior  pelvic  X-ray  examination  was
erformed  under  ﬂuoroscopy  and  digital  images  were
ecorded.
Vaginal  ultrasound  was  performed  with  a  Voluson  E8  (Gen-
ral  Electric,  Vélizy,  France)  and  a 3D  vaginal  RC  5-9D  probe.
D-US  was  ﬁrst  performed  to  study  the  uterus’  morphol-
gy,  volume  of  the  uterus,  presence  of  uterine  ﬁbroids  or
denomyosis,  endometrial  thickness  and  the  ovaries.
Microinserts  were  identiﬁed  in  2D  mode  and  their  rela-
ionship  with  the  interstitial  portion  of  the  fallopian  tubes
nd  the  uterus  were  analyzed.  Maintaining  the  probe  in  a
agittal  section  of  the  uterus,  we  then  realized  a 3D  acqui-
ition.  The  3D  images  allowed  obtaining  a coronal  section
f  the  uterus  showing  the  two  microinserts  on  the  same
mage.  If  the  two  microinserts  were  not  visualized  in  the
ame  section,  two  coronal  images  were  generated.
Hysterosalpingography  (HSG)  was  secondly  performed  at
east  three  months  after  hysteroscopic  sterilization  to  ver-
fy  tubal  occlusion  only  when  the  microinserts  appeared  not
orrectly  positioned  on  pelvic  X-rays  and/or  3D-US  by  the
adiologist  or  when  they  were  considered  too  proximal  into
he  uterine  cavity  by  the  gynecologist  who  performed  the
ysteroscopic  procedure.
An  initial  pelvic  X-ray  examination  (Opera  Swing,
umerix,  Créteil,  France)  was  performed  before  contrast
gent  administration.  A  catheter  was  then  used  to  instil-
ate  10  mL  of  iodinated  contrast  material  (Hexabrix  320,
uerbet,  Roissy-Charles  de  Gaulle,  France,  10  mL)  into  the
terine  cavity  and  digital  images  were  recorded  [18].
mage analysis
he  reading  of  3D-US,  pelvic  X-ray  and  hysteroscopy  exam-
nations  was  retrospectively  done  by  one  radiologist  with
our  years  of  experience.  In  case  of  doubtful  images  a  sec-
nd  radiologist  with  ten  years  of  experience  reviewed  the
mages.
On  pelvic  X-ray  examination,  two  parameters  were
valuated.  The  ﬁrst  parameter  was  the  orientation  and
ymmetrical  deployment  of  the  devices  on  the  basis  of
isualization  of  both  devices  in  the  pelvic  area,  horizontal
rientation  without  angulation,  and  symmetrical  appear-
nce.  The  second  parameter  was  the  distance  between
he  two  proximal  markers  of  the  devices,  which  is  nor-
ally  <4  cm,  which  represents  the  average  distance  between
he  two  tubal  ostia.
On  3D-US,  three  parameters  were  studied.
The  position  of  the  microinserts  was  considered  correct
r  incorrect  (Fig.  1):  a  correct  position  consisted  of  a  per-
ect  position  with  an  isthmic  portion,  an  interstitial  portion
nd  an  intra-uterine  portion  or  a sub  optimal  position  with
n  isthmic  portion  and  an  interstitial  portion  or  with  an
nterstitial  portion  and  an  intra-uterine  portion.  An  incor-
ect  position  consisted  of  a  distal  position  with  a  device  into
he  distal  portion  of  the  fallopian  tube  without  interstitial
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Figure 1. Position of Essure devices on 3D-US. The position is correct if the device is in the interstitial portion of the Fallopian tube: a:
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Rperfect position with an isthmic portion, an interstitial portion and 
and an interstitial portion or with an interstitial portion and an intr
portion  or  an  unseen  microinsert  or  a  non-interpretable
examination.
The  uterus  volume  was  calculated  and  presence  of
morphological  abnormalities  (myoma,  adenomyosis)  were
recorded  (Table  1).
Finally,  the  distance  between  the  two  microinserts  was
calculated  by  measuring  the  distance  between  the  two  prox-
imal  markers  of  the  microinserts  in  the  coronal  section  of
3D-US.  As  on  pelvic  X-ray  this  distance  is  normally  inferior  to
4  cm  except  if  there  is  a  morphological  uterus  abnormality,
which  could  explain  a  normal  increase  of  this  distance.
The  symmetrical  deployment  and  the  distance  between
the  proximal  markers  of  the  devices  were  assessed  on  hys-
terosalpingography.  After  contrast  medium  instillation,  we
evaluated  the  presence  or  absence  of  tubal  occlusion.  Tubal
patency  was  reported  if  the  contrast  agent  was  visible  into
the  Fallopian  tube  past  the  microinserts  or  if  it  leaked  into
the  peritoneal  cavity.
Table  1  Population  characteristics.
Study  population  44
Age  41.7  ±  3.7
2D  and  3D-US  44
Pelvic  X-ray  44
Hysterosalpingography  9
Intrauterine  device  3
Volume  of  the  uterus  (cc)  95.7  (29—211)
Uterus  morphological  abnormalities  Myoma  4
Adenomyosis  9
This table summarizes the characteristics of the population
in our study. Forty-four patients underwent two and three
dimensional ultrasound (2D-US and 3D-US) and pelvic X-ray.
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tatistical analysis
ategorical  variables  were  expressed  as  proportions,  per-
entages  frequency.  Continuous  variables  were  expressed  as
ean  and  standard  deviations.
The  Mac  Nemar  test  (SAS  version  9.2,  Cary,  NC  25513,
SA)  was  used  to  compare  the  performance  of  3D-US  and
elvic  X-rays.  The  paired  Student  t-test  (SAS  version  9.3,
ary,  NC  25513,  USA)  was  used  to  compare  the  distance
etween  the  two  proximal  markers  of  the  devices  in  3D-US
nd  in  pelvic  X-ray.  A  P  value  <  0.05  was  considered  statisti-
ally  signiﬁcant.
esults
ourty-four  women  with  a  mean  age  of  41.7  years  ±  3.7
SD),  a  mean  gravity  of  2.87  ±  0.92  and  mean  parity  of
.45  ±  2.37  were  included.  Study  population  characteristics
re  described  in  Table  1.
The  correct  orientation  and  symmetric  deployment  was
onﬁrmed  in  41/44  patients  (93%)  on  pelvic  X-ray  examina-
ion.  The  distance  between  the  two  proximal  markers  of  the
icroinserts  was  <4  cm  in  39/44  patients  (89%)  on  pelvic  X-
ay  examination.  Finally,  pelvic  X-ray  examination  conﬁrmed
orrect  positioning  of  the  two  microinserts  in  36/44  patients
82%)  (Table  2).
On  3D-US,  the  mean  uterus  volume  was  95.7  cc3 (±41.09
SD])  (Table  2).
Morphological  abnormalities  of  the  uterus  were  found  in
3/44  patients  (30%);  four  women  had  myoma  and  9  had
denomyosis.  The  distance  between  the  two  devices  on  2D-
S  was  measurable  only  in  13  patients.
When  the  two  microinserts  were  visible  (41/44  women,
3%),  3D-US  conﬁrmed  their  correct  position  in  the  inter-
titial  portion  of  the  fallopian  tube  in  38/41  women  (93%)
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Table  2  Results  for  the  Essure  position  observed  on  pelvic  X-ray,  3D-US  and  hysterosalpyngography  in  44  women.
Correct  Incorrect
Symmetric  deployment  on  pelvic  X-ray  41/44  (93%)  3/44  (7%)
Distance  between  the  two  proximal  markers  on  pelvic  X-ray  39/44  (89%)  5/4  (11%)
Position  on  pelvic  X-ray  36/44  (82%)  8/44  (18%)
Visualization  of  the  two  devices  on  3D-US 41/44  (93%) 3/44  (7%)
Position  on  3D-US 38/44  (86%) 6/44  (14%)
HSG  5/9  (55%)
Tubal  patency
3/5  (60%)
4/9 (45%)
Tubal  patency
0/4  (0%)
This table summarizes the results for the Essure position observed on pelvic X-ray, 3D-US and HSG. According to the criteria of symmetric
deployment and the distance inferior to 4 cm between the two proximal markers the Essure microinserts appeared correctly positioned
on pelvic X-ray in 36/44 patients (82%). When they were visible and according to the Legendre description [6], the Essure microinserts
appeared correctly positioned in 38/44 patients (86%) on 3D-US.
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dicroinserts  were  considered  incorrectly  positioned  on  3D-
S  in  6/44  women  (14%)  (Fig.  2).
Devices  were  considered  correctly  positioned  with  3D-
S  and  pelvic  X-ray  in  33/44  patients  (75%)  (Fig.  3).  In  2/9
atients  with  adenomyosis,  the  distance  between  the  two
evices  was  >4  cm  while  the  devices  were  placed  correctly
n  3D-US.  The  uterine  volume  was  enlarged  in  these  patients.
ne  woman  with  cornual  myoma,  ipsilateral  microinsert  was
ot  visualized  on  3D-US.  In  this  woman,  pelvic  X-ray  exami-
ation  conﬁrmed  correct  positioning.
No  signiﬁcant  differences  between  pelvic  X-rays  and  3D-
S  for  determining  the  correct  position  of  microinserts  were
ound  (P  =  0.41).  No  signiﬁcant  differences  between  pelvic
-rays  and  3D-US  to  measure  the  distance  between  the  two
roximal  markers  of  the  devices  were  observed  (P  =  0.0522).
Among  the  nine  women  who  had  hysterosalpingography
t  least  three  months  after  hysteroscopic  sterilization.
Five  were  found  to  have  the  two  microinserts  were  cor-
ectly  positioned  on  3D-US  and  on  pelvic  X-ray,  but  tubal
atency  was  observed  in  3  women  (Fig.  4).  In  four  women
ne  or  two  devices  were  not  correctly  positioned  on  pelvic
-ray  and/or  3D-US  but  no  tubal  patency  was  observed.iscussion
n  our  study,  we  compared  the  performance  of  pelvic  X-
ay  and  3D-ultrasound,  which  has  never  been  done  in  the
c
p
t
igure 2. Incorrect position on pelvic X-ray and 3D-US: a: on pelvic X
evices is greater than 4 cm (A = 76.6 mm); b: On 3D-US, the microinsertiterature.  We  showed  that  the  Essure  microinserts  were  cor-
ectly  positioned  in  82%  on  pelvic  X-ray  and  86%  on  3D-US.
f  the  microinserts  were  not  correctly  positioned,  patients
nderwent  HSG  to  conﬁrm  tubal  occlusion.  In  the  absence  of
ubal  occlusion,  another  sterilization  method  can  be  used.
The  hysteroscopic  sterilization  with  Essure  devices  has
ecome  a worldwide  alternative  to  laparoscopic  steriliza-
ion  [1,23—28]. This  technique  requires  an  evaluation  of
he  microinsert  position  three  months  after  the  procedure
6,12].  Indeed  the  ﬁbrotic  reaction  leading  to  tubal  occlu-
ion  and  permanent  sterilization  [29]  is  only  possible  if  the
oils  are  in  the  interstitial  portion  of  the  fallopian  tubes  [12].
Essure  devices  consist  of  an  inner  radio  opaque  stainless
teel  part,  and  an  outer  nickel  titanium  alloy  surrounded  by
olyethylene  terephtalate  ﬁbers  [6,12,30]  (Fig.  5).
The  outer  spiral  is  designed  to  induce  ﬁbrotic  reaction
ithin  1  to  3  months  leading  to  permanent  tubal  occlusion
31]. An  optimal  positioning  of  Essure  device  is  necessary
o  obtain  ﬁbrotic  reaction  and  subsequently  tubal  occlusion
12]. After  the  procedure,  the  patients  have  usually  mod-
rate  pain  and  spotting  [22]  but  the  complications  such  as
xpulsion,  perforation  or  another  incorrect  position  of  the
evices  [22]  are  rare.  The  pregnancy  rate  after  satisfactory
lacement  reported  in  the  literature  is  0.09%  [5].Pelvic  X-ray  examination  is  recommended  in  Europe  to
heck  for  correct  positioning  of  microinserts.  In addition,
elvic  X-ray  clearly  demonstrates  the  devices  and  the  poten-
ial  complications  such  as  detachment  or  fracture  of  the
-ray (2a), the distance between the proximal markers of the two
s are too distal without interstitial portion (white arrows).
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Figure 3. Correct position of Essure device. This ﬁgure illustrates a correct position of Essure devices on both pelvic X-ray and 3D-US:
a: on pelvic X-ray examinationthe devices has a symmetric deployment and the distance between the two proximal markers was less than
4 cm (A = 29 mm); b: on coronal section generated with 3D-US the microinserts are correctly positioned into the interstitial portion of the
Fallopian tube (white arrows).
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mFigure 4. Unilateral tubal patency: a: on pelvic X-ray examinatio
markers of the devices was less than 4 cm; b: on hysterosalpyngogr
device.  In  this  regard,  Franchini  et  al.  showed  stable  posi-
tion  of  microinsert  on  pelvic  X-ray  at  3  months  and  5  years
[29].  However,  others  authors  have  reported  low  degrees  of
reproducibility  for  pelvic  X-rays  [32].  In  one  study,  six  read-
ers  (three  radiologists  and  three  gynaecologists)  evaluated
47  pelvic  X-ray  examinations  three  months  after  hystero-
scopic  sterilization  [32].  The  reproducibility  of  the  reading
expressed  as  kappa  values  was  0.52  for  radiologists  and
0.09  for  gynaecologists.  The  conclusion  of  this  study  was  to
e
n
(
Figure 5. Essure® micro insert. The Essure (Conceptus, Inc., San Carlo
steel part, and an outer nickel titanium alloy surrounded by polyethylene devices were symmetric and the distance between the proximal
 we observed tubal patency on the left side.
ot  recommend  pelvic  X-rays  because  of  poor  interobserver
greement  even  for  radiologists.
According  to  Pachy  et  al.  [1]  the  pelvic  X-ray  examina-
ion  allows  assessing  the  orientation  and  the  symmetry  of
icroinserts  but  does  not  appreciate  the  relation  of  the
icroinserts  with  the  surrounding  soft  tissues.  This  is  an
asy,  non-expensive  and  painless  but  ionizing  technique  that
eeds  to  be  taken  into  account  especially  for  young  women
the  average  dose  delivered  for  a  pelvic  X-ray  was  around
s, CA, USA) microinsert consists of an inner radio opaque stainless
e terephtalate ﬁbers.
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Figure 6. Enlarged uterus with diffuse adenomyosis. On pelvic X-ray (a), the distance between the proximal markers of the two devices
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pas greater than 4 cm (C = 47.4 mm). On the coronal section gener
ut the microinserts (white arrows) were visible into the interstitia
00  cGy.cm2 or  0.7  mSv  in  our  study).  Pelvic  X-ray  measures
he  distance  between  the  two  devices  but  has  no  idea  about
heir  real  position  into  the  fallopian  tubes.  In  our  study,  we
ave  shown  that  this  technique  failed  to  represent  the  real
osition  of  microinserts  in  frequent  uterine  abnormalities
uch  as  enlarged  uterus  because  of  adenomyosis,  myoma  or
ngulated  fallopian  tubes  (Fig.  6).
The  distance  can  also  be  falsely  right  because  of  reader’s
istake  in  identifying  the  proximal  part  of  one  device.
3D-US  seems  a  promising  alternative  to  pelvic  X-ray  to
onﬁrm  the  correct  position  of  Essure  microinserts.  It  is  an
asy,  non-expensive  and  non-ionizing  technique.  Thiels  et  al.
17],  compared  2D-US  and  3D-US  to  check  the  position  of
ssure  microinserts  in  ﬁfty  patients.  In  this  study,  the  2D  and
D-US  examinations  allowed  to  conﬁrm  the  correct  position
f  microinserts  in  84%  of  cases.  As  in  our  study,  the  position
f  microinsert  was  evaluated  with  a  transverse  section  of
he  uterus  on  2D-US  and  with  a  coronal  section  of  the  uterus
n  3D-US.  The  3D  acquisition  provided  the  best  observation
f  the  relationship  between  the  microinserts,  the  uterine
avity  and  the  Fallopian  tubes.  It  allowed  assessing  the  mor-
hology  and  pathology  of  the  uterus  and  the  fallopian  tubes
ﬁ
i
h
i
igure 7. Intra-uterine portion assessment: a: on pelvic X-ray, the devic
f the two devices was less than 4 cm (A = 15.8 mm); b: on 3D-US, the 
ortion visible into the cavity.with 3D-US (b), the uterus was enlarged with diffuse adenomyosis
tion of the fallopian tubes.
hat  can  be  responsible  of  increased  distance  between  the
evices  or  falsely  abnormal  angulation  [1,6,12]. In  this  study,
atients  underwent  systematically  ultrasound  but  pelvic  X-
ay  was  used  only  in  doubtful  cases.  Unlike  our  study,  there
as  no  comparison  between  these  two  imaging  techniques.
Legendre  et  al.  [12]  compared  3D-US  and  HSG  to  analyze
icroinserts’  position  in  33  patients  and  they  showed  that
D-US  was  reliable  in  this  indication.
In  our  study,  HSG  was  only  performed  in  particular  cases
orresponding  to  20%  of  the  patients.  Indeed  we  consid-
red  that  this  examination  was  expensive,  ionizing  and
otentially  painful  to  be  used  systematically.  Hysterosalpin-
ography  remains  the  gold  standard  imaging  in  USA  because
t  is  the  only  imaging  technique  that  reﬂects  tubal  patency.
ccording  to  Lazarus  et  al.  [18],  the  hysterosalpingography
s  necessary  to  check  the  position  of  Essure  devices  and  to
onﬁrm  tubal  occlusion.  But  since  2002  the  success  rate  of
he  procedure  is  superior  to  90%,  the  physiopathology  of  the
brosis  induced  by  the  microinsert  is  well  known  and  accord-
ng  to  Leary  et  al.  [33], only  15  pregnancies  among  66  000
ysteroscopic  tubal  sterilizations  (0.02%)  were  described
n  patients  with  devices  correctly  positioned  on  pelvic
es were symmetric and the distance between the proximal markers
right device (white arrow) was too proximal with an intra uterine
 and
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[Evaluation  of  tubal  microinserts  position  using  3D  ultrasound
X-ray,  ultrasonography  or  HSG.  Moreover  in  case  of  surgical
tubal  ligation,  no  control  of  the  tubal  occlusion  is  performed
after  the  procedure  even  if  several  cases  of  intra  uterine  or
ectopic  pregnancies  were  also  described  [34—36]  and  the
annual  pregnancy  rate  varies  from  0  to  2%  [37].  In  Jost
et  al.’s  study,  the  total  pregnancy  rate  after  Essure  pro-
cedure  was  1.09/1000  (58  pregnancies)  but  only  one  case
was  interpreted  as  a  ‘‘real  failure’’  of  Essure  sterilization
implant  with  a  correct  placement  on  pelvic  X-ray  [38].
We  observed  a  tubal  patency  in  HSG  in  3/5  patients  with
correctly  positioned  microinserts  that  is  also  described  in
the  literature  [18].  In  these  cases  the  intra  uterine  portion
of  the  devices  was  superior  to  7  mm  (mean  15  mm)  on  3D-
US.  This  speciﬁc  criteria  is  not  actually  taken  into  account  to
assess  the  correct  positioning  of  the  devices.  Nethertheless,
it  may  represent  a  new  parameter  to  assess  the  position  of
microinserts  and  could  explain  secondary  pain,  menorrhagia
and  tubal  patency  (Fig.  7).
Our  study  had  some  limitations.  First,  the  small  num-
ber  of  patients  with  not  correctly  positioned  device  because
of  the  success  rate  of  the  procedure  superior  to  90%  [31].
This  could  explain  the  lack  of  signiﬁcant  difference  observed
between  pelvic  X-ray  and  3D-US;  indeed  to  demonstrate  the
superiority  of  3D-US  compared  to  pelvic  X-ray,  60  not  cor-
rectly  positioned  devices  would  have  been  necessary.
Secondly,  we  did  not  perform  systematically  a  hysteros-
alpingography  considered  as  the  gold  standard  in  USA  to
verify  the  tubal  occlusion  because  it  is  an  ionizing  and  poten-
tially  painful  procedure.  Furthermore,  the  manufacturer  in
Europe  does  not  recommend  systematically  HSG  but  only
in  particular  cases  [22,39].  Thirdly,  our  study  does  not  study
the  new  imaging  techniques  such  as  the  EOS  system  in  pelvis
exploration  [40].
Finally,  our  study  compared  the  performance  of  3D-US
and  pelvic  X-ray  to  assess  the  correct  positioning  of  the
devices  but  it  may  be  interesting  to  compare  3D-US  and
2D-US.
Conclusion
In  conclusion,  our  results  show  that  3D-US  and  pelvic  X-
ray  examination  have  similar  capabilities  in  the  evaluation
of  the  positioning  of  the  microinserts.  Because  3D-US  is  a
non-ionizing  method,  which  gives  more  morphological  infor-
mation  than  pelvic  X-rays,  it  should  replace  pelvic  X-ray
examination  to  evaluate  the  positioning  of  the  microinserts
after  hysteroscopic  tubal  sterilization.
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